Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06062238
Other study ID # Gates MRI-TBV02-301
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 5, 2024
Est. completion date April 2028

Study information

Verified date April 2024
Source Bill & Melinda Gates Medical Research Institute
Contact Gates MRI
Phone +1 857 702 2108
Email clinical.trials@gatesmri.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mtb vaccine when administered intramuscularly (IM) on a 0,1-month schedule to adolescents and adults. This trial will be conducted in 3 cohorts: Interferon gamma release assay (IGRA)-positive Cohort, IGRA-Negative Cohort and Human Immunodeficiency virus (HIV) Cohort.


Recruitment information / eligibility

Status Recruiting
Enrollment 20000
Est. completion date April 2028
Est. primary completion date April 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 44 Years
Eligibility Inclusion criteria: - Capable of giving informed consent or informed assent (as appropriate). For participants below the age of consent, the participant's parent, or legally authorized representative (LAR) will be required to sign a statement of informed consent, in addition to the minor's signed statement of assent. - In the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of diary cards as applicable, and return for follow-up visits). - Agree to actively stay in contact with the trial site for the duration of the trial for the participants own safety. - Agree to provide updated contact information as necessary, and have no current plans to relocate from the trial area for the duration of the trial. - Healthy, or with preexisting stable disease, as established by medical history and physical examination and as determined by the investigator. - Negative sputum Xpert Ultra or similar assay result at screening. - Both males and females are included. Females are included with restrictions. Females must either be of non-childbearing potential, defined as pre-menarche, have a history of either current tubal ligation, hysterectomy, or ovariectomy, or post-menopause, or, if she is of childbearing potential, she has practiced abstinence from penile-vaginal intercourse or adequate contraception for 28 days prior to vaccination, has a negative pregnancy test on the day of screening and the day of first vaccination, and agrees to continue abstinence or adequate contraception until 2 months after the second dose of trial intervention. - HIV-negative test result at screening (IGRA-Positive Cohort and IGRA-Negative Cohort only). - HIV Cohort only: Participants with documented HIV infection who fulfill all of the following criteria: 1. Have reactive anti-HIV antibody at screening. 2. Have been on antiretroviral therapy (ART) for at least 3 consecutive months at screening and agree to remain on ART throughout the trial. 3. Have documented HIV Ribonucleic acid (RNA) <200 copies per milliliter (/mL) at screening. 4. Have Cluster of differentiation (CD)4+ cell count =200 cells/microliter (µL) at screening. 5. Have had Tuberculosis preventive therapy (TPT) in the past and are not receiving TPT at the time of screening, according to the judgment of the investigators. 6. Have an IGRA-positive or negative result at screening. Exclusion criteria: - Current TB, or history of TB or treatment for TB disease. - Clinical suspicion of pulmonary TB at screening, defined as a participant presenting with one or more of the following signs or symptoms: unexplained cough, unexplained fever, night sweats, unintentional weight loss, hemoptysis, pleuritic chest pain. - Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the participant will comply with the protocol, or that will interfere with the assessments or the safety of the participant. - Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., invasive, or malignant cancers), other than HIV infection in the HIV Cohort. - Known bleeding disorder that is considered a contraindication to intramuscular injection or phlebotomy. - Any cytotoxic drugs or administration of medications known to have a major impact on the immune system, as determined by the investigator, within 90 days prior to Day 1. These include immune globulin, blood, or blood products, potent immunosuppressants and immunomodulators, and systemic corticosteroids (exceeding 20 mg/day prednisone equivalent). Inhaled, topical, and intra-articular corticosteroids are allowed. - Planned receipt of blood, or blood products during the trial period. - Receipt or planned receipt of any vaccine in the period starting 28 days before, and ending 28 days after, each dose of the trial vaccine. - History of previous administration of an experimental Mtb vaccine including M72/AS01E in a previous trial. - History of allergy or hypersensitivity to the trial intervention, excipients, or related Substances. - An indeterminate IGRA test result at screening - Female participants with any one of the following conditions: currently pregnant or lactating; having positive serum pregnancy test during the screening window, positive urine pregnancy test on Day 1, planning a pregnancy within 2 months after completion of the vaccination series. - Only in the HIV Cohort: Safety laboratory values at screening that are of concern, based on investigator's judgment. Note that preexisting stable chronic disease will not necessarily lead to exclusion, especially if laboratory values are graded as mild. - Participation in an interventional clinical trial in which the participant has been or will be exposed to an investigational product (pharmaceutical product or device), within 28 days prior to signing consent or assent, or during the trial period. - Individuals who are acting as personnel for this trial, or who have immediate family members (brother, sister, child, parent, or the spouse/partner) who are acting as personnel for this trial. - Child in Care, defined as a child who is under the care (control or protection) of an agency, organization, institution or entity by the courts, the government body, acting in accordance with powers conferred in them by law or regulations. The definition of a child in care can include a child who is cared for by foster parents or living in a care home or institution, provided that the arrangements fall within the definition above. The definition of a child in care does not include a child who is adopted or has an appointed LAR. - Participants who had a Tuberculin Skin Test (TST) within 6 months prior to Day 1.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine
Participants will receive an intramuscular dose of M72 (recombinant fusion protein) reconstituted with AS01E-4 (an adjuvant system), on Day 1 and Day 29.
Placebo
Participants will receive an intramuscular dose of normal saline (0.9 percent [%] sodium chloride [NaCl]), on Day 1 and Day 29.

Locations

Country Name City State
Indonesia Gates MRI Investigational Site Bandung
Indonesia Gates MRI Investigational Site Depok
Indonesia Gates MRI Investigational Site Jakarta
Indonesia Gates MRI Investigational Site Jakarta
Indonesia Gates MRI Investigational Site Jakarta
Kenya Gates MRI Investigational Site Eldoret
Kenya Gates MRI Investigational Site Homa Bay
Kenya Gates MRI Investigational Site Kericho
Kenya Gates MRI Investigational Site Kilifi
Kenya Gates MRI Investigational Site Kisumu
Kenya Gates MRI Investigational Site Machakos
Kenya Gates MRI Investigational Site Mombasa
Kenya Gates MRI Investigational Site Nairobi
Kenya Gates MRI Investigational Site Nairobi
Malawi Gates MRI Investigational Site Chichiri
Malawi Gates MRI Investigational Site Lilongwe
Mozambique Gates MRI Investigational Site Manhica
Mozambique Gates MRI Investigational Site Maputo
South Africa Gates MRI Investigational Site Bloemfontein
South Africa Gates MRI Investigational Site Brits
South Africa Gates MRI Investigational Site Cape Town
South Africa Gates MRI Investigational Site Cape Town
South Africa Gates MRI Investigational Site Cape Town
South Africa Gates MRI Investigational Site Cape Town
South Africa Gates MRI Investigational Site Cape Town
South Africa Gates MRI Investigational Site Cape Town
South Africa Gates MRI Investigational Site Cape Town
South Africa Gates MRI Investigational Site Durban
South Africa Gates MRI Investigational Site Durban
South Africa Gates MRI Investigational Site Durban
South Africa Gates MRI Investigational Site East London
South Africa Gates MRI Investigational Site Johannesburg
South Africa Gates MRI Investigational Site Johannesburg
South Africa Gates MRI Investigational Site Johannesburg
South Africa Gates MRI Investigational Site Johannesburg
South Africa Gates MRI Investigational Site Jouberton
South Africa Gates MRI Investigational Site Kimberley
South Africa Gates MRI Investigational Site Klerksdorp
South Africa Gates MRI Investigational Site Ladysmith
South Africa Gates MRI Investigational Site Middelburg
South Africa Gates MRI Investigational Site Mtubatuba
South Africa Gates MRI Investigational Site Paarl
South Africa Gates MRI Investigational Site Port Elizabeth
South Africa Gates MRI Investigational Site Pretoria
South Africa Gates MRI Investigational Site Rustenburg
South Africa Gates MRI Investigational Site Soweto
South Africa Gates MRI Investigational Site Soweto
South Africa Gates MRI Investigational Site Soweto
South Africa Gates MRI Investigational Site Tembisa
South Africa Gates MRI Investigational Site #1 Tembisa
South Africa Gates MRI Investigational Site Vereeniging
South Africa Gates MRI Investigational Site Worcester
Vietnam Gates MRI Investigational Site C?n Tho
Vietnam Gates MRI Investigational Site Hanoi
Vietnam Gates MRI Investigational Site Ho Chi Minh city
Vietnam Gates MRI Investigational Site #1 Ho Chi Minh City
Zambia Gates MRI Investigational Site Lusaka
Zambia Gates MRI Investigational Site Lusaka
Zambia Gates MRI Investigational Site Lusaka
Zambia Gates MRI Investigational Site Ndola

Sponsors (3)

Lead Sponsor Collaborator
Bill & Melinda Gates Medical Research Institute Bill and Melinda Gates Foundation, Wellcome Trust

Countries where clinical trial is conducted

Indonesia,  Kenya,  Malawi,  Mozambique,  South Africa,  Vietnam,  Zambia, 

Outcome

Type Measure Description Time frame Safety issue
Primary IGRA-Positive Cohort: Number of participants with laboratory-confirmed pulmonary tuberculosis (TB) Laboratory-confirmed pulmonary TB case is defined as a participant with suspected pulmonary TB presenting with one or more of the following signs or symptoms: unexplained cough, unintentional weight loss, hemoptysis, unexplained fever, night sweats, pleuritic chest pain; who has least 2 positive Mtb test results (positive Mtb culture and/or positive test result from Xpert Ultra or similar assay, excluding "trace positive"), from the same or from different sputum samples collected during the 3 suspected TB visits, preferably within a 7-day time frame, before initiation of TB treatment. Up to Month 49
Secondary IGRA-Negative Cohort: Number of participants with sustained QuantiFERON®-TB Gold Plus assay conversion Up to Month 49
Secondary IGRA-Negative Cohort: Number of participants with laboratory-confirmed pulmonary TB Up to Month 49
Secondary HIV Cohort: Number of participants with laboratory-confirmed pulmonary TB Up to Month 49
Secondary IGRA-Positive Cohort: Number of participants with laboratory-confirmed pulmonary TB (Less stringent laboratory-confirmed pulmonary TB case definition) Laboratory-confirmed pulmonary TB case is defined as a participant with suspected pulmonary TB presenting with one or more of the following signs or symptoms: unexplained cough, unintentional weight loss, hemoptysis, unexplained fever, night sweats, pleuritic chest pain; who has at least 1 positive Mtb culture or at least 1 positive result from Xpert Ultra or similar assay (excluding "trace positive"), from the same or from different sputum samples collected during the 3 suspected TB visits, preferably within a 7-day time frame, before initiation of TB treatment.
Compose
Up to Month 49
Secondary All Cohorts: Number of participants with solicited adverse events (AEs) Up to 7 days
Secondary All Cohorts: Number of participants with unsolicited AEs Up to 28 days
Secondary All Cohorts: Number of participants with serious adverse events (SAEs) Up to Month 13
Secondary All Cohorts: Number of participants with potential immunemediated diseases (pIMDs) Up to Month 13
Secondary All Cohorts: Number of participants with SAEs related to trial participation Up to Month 49
Secondary All cohorts: Number of participants with geometric mean concentration (GMC) of M72-specific antibodies At Day 1, Month 1, Month 2, Month 7, Month 13, Month 37, and Month 49
Secondary All cohorts: Number of participants with seropositivity of M72-specific antibodies At Day 1, Month 1, Month 2, Month 7, Month 13, Month 37, and Month 49
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2